Evidence map›Paper›PMID 28490735›Full record

ArticleScientific reports2017

Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.

Vinod Kumar, Amit Kumar Chaudhary, Yuxiang Dong, Haizhen A Zhong, Goutam Mondal, Feng Lin, Virender Kumar, Ram I Mahato

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. The Role of Smoothened in Cancer.International journal of molecular sciences · 2020
    Review
  11. Article
  12. Article
  13. Review
  14. Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2019
    Article
  15. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer.The Journal of pharmacology and experimental therapeutics · 2019
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vinod KumarDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Amit Kumar ChaudharyDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Yuxiang DongDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Haizhen A ZhongDepartment of Chemistry, University of Nebraska at Omaha, 6001 Dodge Street, Omaha, NE, 68182, USA.
Goutam MondalDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Feng LinDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Virender KumarDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Ram I MahatoDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, 68198, USA. ram.mahato@unmc.edu.
University of Nebraska Medical Center · USUniversity of Nebraska at Omaha · US

Funding

Polymeric Nanomedicines of Hedgehog Inhibitor and miRNA for Treating Pancreatic CancerR01GM113166 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., MAHATO, RAM I. · 2015 to 2018
$1.4M
NIGMS NIH HHS R01 GM113166
6 · The paper itself

Abstract

Hedgehog (Hh) pathway is involved in epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) maintenance resulting in tumor progression. GDC-0449, an inhibitor of Hh pathway component smoothened (Smo) has shown promise in the treatment of various cancers including pancreatic cancer. However, the emergence of resistance during GDC-0449 treatment with numerous side effects limits its use. Therefore, here we report the design, synthesis and evaluation of novel GDC-0449 analogs using N-[3-(2-pyridinyl) phenyl] benzamide scaffold. Cell-based screening followed by molecular simulation revealed 2-chloro-N

Indexed as

Drug DesignAnilidesAnimalsAntineoplastic AgentsApoptosisBiomarkers, TumorCarcinogenesisCell Cycle CheckpointsCell Line, TumorCell MovementDrug Evaluation, PreclinicalHedgehog ProteinsHumansInhibitory Concentration 50MaleMiceAnilidesAntineoplastic AgentsBiomarkers, TumorHedgehog ProteinsHhAntag691PyridinesSmoothened ReceptorSMO protein, human

Identifiers

PMID28490735
PMCPMC5431907
OpenAlexW2610280124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.